CliffBio
small molecule

COMBOGESIC

ACETAMINOPHEN; IBUPROFEN

Loss of exclusivityFebruary 2039latest FDA-listed patent expiry
CompanyAFT →See this company's full patent-cliff portfolio

Drug detail

Brand nameCOMBOGESIC
Active ingredientACETAMINOPHEN; IBUPROFEN
Strength325MG;97.5MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2023
Marketing statusRX

Listed patents

PatentExpiresType
11534407February 2039product
11197830February 2039product

Regulatory exclusivity

CodeExpires
NPMarch 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

COMBOGESIC patent cliff — loss of exclusivity February 2039 | CliffBio